= Emerging. More than 5 years before clinical availability. (16.60%, 2024)
= Expected to be clinically available in 1 to 4 years. (37.02%, 2024)
= Clinically available now. (46.38%, 2024)
MSACL 2024 : Session

MSACL 2024 Abstract

Self-Classified Topic Area(s): Small Molecule > none > none
Podium Presentation in Steinbeck 1 on Thursday at 16:00 (Chair: Briana Fitch)

Discussion on Impending FDA Regulation of Clinical Lab LDTs

Discussion Session (Presenter)

Abstract

Panel Discussion with Stephen Master, Andy Hoofnagle, Gwen McMillan, Dennis Dietzen and Kara Lynch.

Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no